ClinicalTrials.gg
CompletedNCT00630851Updated Mar 5, 2015

A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

A Phase 3 interventional study of Donepezil (Aricept) and Placebo in Alzheimer Disease, sponsored by Pfizer. Completed at 53 sites in Sweden. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
7th of 58
249 · median 79
Started
2002
with 1 other
Phase 3
10 of 60
1 open now
Registered
23rd of 60
by date
Lead sponsor
4 of 60
Pfizer

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 7th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2002, is one of 10 in phase 3, and was the 23rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Probable or possible Alzheimer's disease
  • Living in skilled nursing home

Exclusion criteria

Exclusion Criteria:

  • Other types of dementia or psychiatric or neurologic disorders
  • Musculoskeletal disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
249 participants (actual)

Study arms

  • Experimental
    1

    Drug: Donepezil (Aricept)

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment

  • DrugPlacebo

    Matching placebo tablets orally once daily for 6 months

06

What researchers measure

Primary outcomes

  1. Change from baseline in modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe) total score

    Time frame: Month 6

  2. Change from baseline in Severe Impairment Battery (SIB) total score

    Time frame: Month 6

Secondary outcomes

  1. Change from baseline in SIB total score

    Time frame: Month 3

  2. Change from baseline in Neuropsychiatric Inventory (NPI) total score

    Time frame: Months 3 and 6

  3. Change from inclusion in Mini Mental State Examination (MMSE) total score

    Time frame: Month 6

  4. Change from baseline in Clinical Global Impression of Improvement (CGI-I) score

    Time frame: Months 3 and 6

  5. Adverse events and laboratory value changes

    Time frame: Months 3 and 6

  6. Change from baseline in modified ADCS-ADL-severe total score

    Time frame: Month 3

07

Study locations

53 sites
  • Pfizer Investigational Site
    Fritsla, Sweden 510 29, Sweden
  • Pfizer Investigational Site
    Alunda, 747 30, Sweden
  • Pfizer Investigational Site
    Aneby, 578 21, Sweden
  • Pfizer Investigational Site
    Avesta, 774 82, Sweden
  • Pfizer Investigational Site
    Åkersberga, 184 33 AKERSBERGA, Sweden
  • Pfizer Investigational Site
    Årsta, 120 54, Sweden
  • Pfizer Investigational Site
    Bengtsfors, 666 30, Sweden
  • Pfizer Investigational Site
    Bergsjö, 820 70, Sweden
  • Pfizer Investigational Site
    Boden, 931 64, Sweden
  • Pfizer Investigational Site
    Borlänge, 781 27, Sweden
  • Pfizer Investigational Site
    Degerfors, 693 22, Sweden
  • Pfizer Investigational Site
    Eskilstuna, 631 88, Sweden
  • Pfizer Investigational Site
    Eskilstuna, 632 23, Sweden
  • Pfizer Investigational Site
    Gislaved, 332 30, Sweden
  • Pfizer Investigational Site
    Gothenburg, 412 75, Sweden
  • Pfizer Investigational Site
    Gullspång, 547 31, Sweden
  • Pfizer Investigational Site
    Gustavsberg, 134 30, Sweden
  • Pfizer Investigational Site
    Hedemora, 776 28, Sweden
  • Pfizer Investigational Site
    Helsingborg, 254 43, Sweden
  • Pfizer Investigational Site
    Ingelstad, 360 44, Sweden
  • Pfizer Investigational Site
    Jönköping, 553 16, Sweden
  • Pfizer Investigational Site
    Kalix, 952 82, Sweden
  • Pfizer Investigational Site
    Karlstad, 656 37, Sweden
  • Pfizer Investigational Site
    Katrineholm, 641 47, Sweden
  • Pfizer Investigational Site
    Kristinehamn, 681 29, Sweden
  • Pfizer Investigational Site
    Lidköping, 531 85, Sweden
  • Pfizer Investigational Site
    Malmö, 205 02, Sweden
  • Pfizer Investigational Site
    Munkfors, 684 23, Sweden
  • Pfizer Investigational Site
    Nässjö, 576 81, Sweden
  • Pfizer Investigational Site
    Oxie, 238 40, Sweden
  • Pfizer Investigational Site
    Östersund, 831 31, Sweden
  • Pfizer Investigational Site
    Partille, 43323, Sweden
  • Pfizer Investigational Site
    Rättvik, 795 21, Sweden
  • Pfizer Investigational Site
    Sandviken, 811 60, Sweden
  • Pfizer Investigational Site
    Särö, 429 13, Sweden
  • Pfizer Investigational Site
    Sjuntorp, 460 20, Sweden
  • Pfizer Investigational Site
    Sollebrunn, 466 30, Sweden
  • Pfizer Investigational Site
    Stockholm, 112 35, Sweden
  • Pfizer Investigational Site
    Stockholm, 116 32, Sweden
  • Pfizer Investigational Site
    Sunne, 686 22, Sweden
  • Pfizer Investigational Site
    Trollhättan, 461 59, Sweden
  • Pfizer Investigational Site
    Tullinge, 146 31, Sweden
  • Pfizer Investigational Site
    Tyreso, 13521, Sweden
  • Pfizer Investigational Site
    Umeå, 901 85, Sweden
  • Pfizer Investigational Site
    Upplands Vasby, 194 04, Sweden
  • Pfizer Investigational Site
    Uppsala, 751 25, Sweden
  • Pfizer Investigational Site
    Vaxjo, 350 04, Sweden
  • Pfizer Investigational Site
    Vaxjo, 352 41, Sweden
  • Pfizer Investigational Site
    Vännäs, 911 82, Sweden
  • Pfizer Investigational Site
    Värnamo, 33185, Sweden
  • Pfizer Investigational Site
    Västerås, 722 11, Sweden
  • Pfizer Investigational Site
    Visby, 621 84, Sweden
  • Pfizer Investigational Site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2008
First posted
Mar 7, 2008
Start
Oct 2002
CompletionActual
Oct 2004
Last update
Mar 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00630851
Lead sponsor
Pfizer
First posted
Mar 7, 2008
Start date
Oct 2002
Completion
Oct 2004
Last update
Mar 5, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion